Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health

You may also be interested in...

China Releases County-level Public Hospital Reform Guidelines

The reforms will slash drug markups and promote the Essential Drug List and traditional Chinese medicine to control medical expenditures.

Asia Spotlight: With Change On The Horizon, Current Business Models In China Are Not Sustainable – So What’s Next?

Health care reforms will turn the China health care market upside now, meaning that pharma companies must prepare for a new sustainable business model.

Bayer Taps Deeper Into Beijing’s Biotech Potential, Renews Partnership With Tsinghua

Latest research deal for Bayer underscores Beijing’s growing importance as a biotech hub.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts